These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37683902)

  • 1. Optimized expression and purification of a human adenosine deaminase in E. coli and characterization of its Asp8Asn variant.
    Jennings MR; Min S; Xu GS; Homayuni K; Suresh B; Haikal YA; Blazeck J
    Protein Expr Purif; 2024 Jan; 213():106362. PubMed ID: 37683902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catalytically active holo Homo sapiens adenosine deaminase I adopts a closed conformation.
    Ma MT; Jennings MR; Blazeck J; Lieberman RL
    Acta Crystallogr D Struct Biol; 2022 Jan; 78(Pt 1):91-103. PubMed ID: 34981765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
    Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
    Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An adenosine deaminase (ADA) allele contains two newly identified deleterious mutations (Y97C and L106V) that interact to abolish enzyme activity.
    Jiang C; Hong R; Horowitz SD; Kong X; Hirschhorn R
    Hum Mol Genet; 1997 Dec; 6(13):2271-8. PubMed ID: 9361033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID): Molecular Pathogenesis and Clinical Manifestations.
    Bradford KL; Moretti FA; Carbonaro-Sarracino DA; Gaspar HB; Kohn DB
    J Clin Immunol; 2017 Oct; 37(7):626-637. PubMed ID: 28842866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tandem mass spectrometry, but not T-cell receptor excision circle analysis, identifies newborns with late-onset adenosine deaminase deficiency.
    la Marca G; Canessa C; Giocaliere E; Romano F; Duse M; Malvagia S; Lippi F; Funghini S; Bianchi L; Della Bona ML; Valleriani C; Ombrone D; Moriondo M; Villanelli F; Speckmann C; Adams S; Gaspar BH; Hershfield M; Santisteban I; Fairbanks L; Ragusa G; Resti M; de Martino M; Guerrini R; Azzari C
    J Allergy Clin Immunol; 2013 Jun; 131(6):1604-10. PubMed ID: 23280131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency.
    Montiel-Equihua CA; Thrasher AJ; Gaspar HB
    Curr Gene Ther; 2012 Feb; 12(1):57-65. PubMed ID: 22348551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The inclusion of ADA-SCID in expanded newborn screening by tandem mass spectrometry.
    la Marca G; Giocaliere E; Malvagia S; Funghini S; Ombrone D; Della Bona ML; Canessa C; Lippi F; Romano F; Guerrini R; Resti M; Azzari C
    J Pharm Biomed Anal; 2014 Jan; 88():201-6. PubMed ID: 24076575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrum of mutations in a cohort of UK patients with ADA deficient SCID: Segregation of genotypes with specific ethnicities.
    Adams SP; Wilson M; Harb E; Fairbanks L; Xu-Bayford J; Brown L; Kearney L; Madkaikar M; Bobby Gaspar H
    Clin Immunol; 2015 Dec; 161(2):174-9. PubMed ID: 26255240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homozygosity for a missense mutation (G20R) associated with neonatal onset adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID).
    Yang DR; Huie ML; Hirschhorn R
    Clin Immunol Immunopathol; 1994 Feb; 70(2):171-5. PubMed ID: 8299233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of a functional human adenosine deaminase in transgenic tobacco plants.
    Singhabahu S; George J; Bringloe D
    Transgenic Res; 2013 Jun; 22(3):643-9. PubMed ID: 23264022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID.
    Sauer AV; Brigida I; Carriglio N; Hernandez RJ; Scaramuzza S; Clavenna D; Sanvito F; Poliani PL; Gagliani N; Carlucci F; Tabucchi A; Roncarolo MG; Traggiai E; Villa A; Aiuti A
    Blood; 2012 Feb; 119(6):1428-39. PubMed ID: 22184407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis for paradoxical carriers of adenosine deaminase (ADA) deficiency that show extremely low levels of ADA activity in peripheral blood cells without immunodeficiency.
    Ariga T; Oda N; Sanstisteban I; Arredondo-Vega FX; Shioda M; Ueno H; Terada K; Kobayashi K; Hershfield MS; Sakiyama Y
    J Immunol; 2001 Feb; 166(3):1698-702. PubMed ID: 11160213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe combined immunodeficiency of reduced severity due to homozygosity for an adenosine deaminase missense mutation (Arg253Pro).
    Hirschhorn R; Yang DR; Insel RA; Ballow M
    Cell Immunol; 1993 Dec; 152(2):383-93. PubMed ID: 8258146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
    Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
    Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.
    Silver JN; Flotte TR
    Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
    Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
    Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.
    Nikolajeva O; Worth A; Hague R; Martinez-Alier N; Smart J; Adams S; Davies EG; Gaspar HB
    J Clin Immunol; 2015 May; 35(4):366-72. PubMed ID: 25875700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine deaminase from Streptomyces coelicolor: recombinant expression, purification and characterization.
    Pornbanlualap S; Chalopagorn P
    Protein Expr Purif; 2011 Aug; 78(2):167-73. PubMed ID: 21511036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine deaminase: functional implications and different classes of inhibitors.
    Cristalli G; Costanzi S; Lambertucci C; Lupidi G; Vittori S; Volpini R; Camaioni E
    Med Res Rev; 2001 Mar; 21(2):105-28. PubMed ID: 11223861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.